Global specialist in serving science enabling customers to make the world healthier, cleaner, and safer through laboratory equipment and services.
Profile & Fundamentals
Thermo Fisher Scientific: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Thermo Fisher Scientific Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Company profile record
Thermo Fisher Scientific Inc
Common Stock · Health Care · Life Sciences Tools & Services
Company
- Company / asset
- Thermo Fisher Scientific Inc
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- HQ
- 🇺🇸 United States
- Head office
- 168 Third Avenue, Waltham, MA, United States, 02451
Leadership & scale
- Chief executive
- Mr. Marc N. Casper
- CEO year born
- 1968
- Full-time employees
- 125K
- Fiscal year end
- December
- IPO date
- 1978-01-13
Fundamentals snapshot
- Market Cap
- USD 241.7B
- P/E
- 34.6x
- Revenue (Q2 26)
- USD 12.0B
- Profit (Q2 26)
- USD 1.7B
- Dividend Yield
- 0.2%
- Revenue (FY 25)
- USD 44.6B
- Shares in public float
- 368.8M
- Insider ownership
- 0.13%
Reporting & identifiers
- Symbol
- TMO.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US8835561023
- Asset ID
- equity_b5649eae-cacd-5a55-b622-d2acb17d1247
Ownership
Shares Outstanding
- Shares outstanding
Top holders
- BlackRock Inc30,427,192 shares · 8.23% · Reported 2026-03-31
- Vanguard Capital Management, LLC24,280,816 shares · 6.57% · Reported 2026-03-31
- State Street Corp16,731,668 shares · 4.53% · Reported 2026-03-31
- CI Private Wealth LLC16,191,744 shares · 4.38% · Reported 2026-06-30
- Vanguard MStar Total Stk Mkt Idx Invest11,833,455 shares · 3.20% · Reported 2026-07-31
- Morgan Stanley - Brokerage Accounts10,863,528 shares · 2.94% · Reported 2026-03-31
- FMR Inc10,776,436 shares · 2.91% · Reported 2026-03-31
View more holders (8)
- Vanguard 500 Index Investor9,754,245 shares · 2.64% · Reported 2026-07-31
- Geode Capital Management, LLC8,407,891 shares · 2.27% · Reported 2026-03-31
- Franklin Templeton Inc6,813,031 shares · 1.84% · Reported 2026-03-31
- JPMorgan Chase & Co6,795,482 shares · 1.84% · Reported 2026-03-31
- T. Rowe Price Associates, Inc.6,315,471 shares · 1.71% · Reported 2026-03-31
- Capital World Investors6,195,370 shares · 1.68% · Reported 2026-06-30
- Vanguard Portfolio Management, LLC6,163,370 shares · 1.67% · Reported 2026-03-31
- Bank of America Corp5,533,403 shares · 1.50% · Reported 2026-03-31
Earnings, Profitability & Valuation
Earnings & Revenue
Revenue, Net Income, and Free Cash Flow
- Revenue
- Free cash flow
- Net income
Valuation
Historical P/E Ratio
- Published P/E
Profitability & Margins
Profitability Margins
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.